Novel Therapeutic Approaches for Chronic Urticaria: Advances and Challenges
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".
Deadline for manuscript submissions: 28 February 2025 | Viewed by 65
Special Issue Editor
Special Issue Information
Dear Colleagues,
Chronic urticaria (CU) is a prevalent and challenging condition characterized by recurring hives and/or angioedema, significantly affecting patients’ quality of life. While progress in understanding CU has led to new therapies, many patients remain unresponsive to standard treatments, underscoring the need for novel approaches.
Recent advances include the development of biologics targeting specific immune pathways, such as anti-IgE and anti-cytokine therapies, which have shown promise in improving treatment outcomes. Additionally, new small molecules and innovative formulations are being explored to enhance efficacy and safety. Personalized medicine, focusing on biomarkers and genetic profiles, is also emerging as a potential game-changer in tailoring treatments to individual patients.
However, challenges persist, including optimizing long-term safety, managing costs, and addressing treatment resistance. In this context, there is growing interest in drug repurposing and combination therapies to enhance therapeutic outcomes and address unmet clinical needs in CU.
This Special Issue invites original research and review articles on the latest therapeutic advancements in CU, including novel biologics, small molecules, personalized treatment strategies, and drug repurposing. Our goal is to highlight cutting-edge developments and explore future directions that will improve CU management and enhance patient care.
Dr. Luis Felipe Ensina
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- chronic urticaria
- current management
- biosimilar pharmaceuticals
- biologic drugs
- monoclonal antibodies
- tyrosine kinase inhibitors
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
